Vincent+Luu

Presentation Part:


 * Organizational design: **

Novo Nordisk has a sustainable business design where corporate responsibility is fully integrated into the board of executives, finance, and the brand. It has a corporation which is able to constantly innovate itself in tune with societal changes, led by ethical principles and in sync with its stakeholders’ expectation, operating in partnerships across sectors, and generating a net positive. It also has an environmental and social impact in the global community.


 * A) ****Organizational Design and Strategic Decisions **

Some strategic decisions Novo has recently made:
 * Temporarily withdrew some products in Greece because the Greek government cut prices by up to 27%. However, Novo still continue to provide insulin in vials. While pricing issues remain unresolved in Greece, they have been able to continue to offer their other products, including modern insulin, with Penfill cartridges in the NovoPen 4 device.
 * They also make decisions based on meeting their long-term goals. The long-term financial targets are set based on their current growth strategy and the current scope of activities. The targets help management establish a balance between growing the business profitably in the near term while ensuring they are able to make investments to support long-term growth.
 * Growing their business profitably and delivering competitive results is the basis of their ability to help patients live better lives, offer an attractive return to their shareholders, and serve all of their stakeholders. Novo believes that the only way to run a sustainable business is to generate strong results on multiple dimensions.


 * B) ****Organizational Design and Co-Evolution **


 * The company has a history of innovation in both product and delivery systems. It has innovated the syringe with a pen-shaped device known as the NovoPen with many generations.
 * Novo Nordisk has a leading position within areas such as homeostasis management, growth hormone therapy and hormone replacement therapy.
 * Novo has created The Oxford Health Alliance (OHA), an open network for sharing IPs and knowledge that allows members from different backgrounds to collaborate to raise awareness and change behaviors, policies and perspectives at every level of society.

[]
 * Short clip about the firm**


 * References:**

[] []  • //The company has a history of innovation in both product and delivery systems. It has innovated the syringe with a pen-shaped device known as the NovoPen with many generations//